Insight Molecular Diagnostics (IMDX) Common Equity (2015 - 2026)

Insight Molecular Diagnostics (IMDX) has 12 years of Common Equity data on file, last reported at -$10.7 million in Q1 2026.

• Quarterly Common Equity fell 204.63% year-over-year to -$10.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$10.7 million (down 204.63% YoY) and the FY2025 annual result came in at -$31.5 million, down 156.35% from the prior year.
• Common Equity advanced to -$10.7 million in Q1 2026 per IMDX's latest filing, from -$31.5 million in the prior quarter.
• The five-year high for Common Equity was $83.2 million in Q2 2022, with the low at -$31.5 million in Q4 2025.
• Average Common Equity over 5 years is $22.4 million, with a median of $20.5 million recorded in 2023.
• Year-over-year, Common Equity retreated 11.82% in 2025 and tumbled 204.63% in 2026.
• Insight Molecular Diagnostics' Common Equity stood at $34.3 million in 2022, then plunged by 40.31% to $20.5 million in 2023, then slumped by 159.97% to -$12.3 million in 2024, then tumbled by 156.35% to -$31.5 million in 2025, then soared by 66.02% to -$10.7 million in 2026.
• Business Quant data shows IMDX's Common Equity at -$10.7 million in Q1 2026, -$31.5 million in Q4 2025, and -$9.2 million in Q3 2025.